https://www.selleckchem.com/pr....oducts/Ilginatinib-h
The results of chronic total occlusion percutaneous coronary intervention (CTO-PCI) trials are inconclusive. Therefore, we studied whether CTO-PCI leads to improvement of clinical endpoints and patient symptoms when combining all available randomised data. This meta-analysis was registered in PROSPERO prior to starting. We performed aliterature search and identified all randomised trials comparing CTO-PCI to optimal medical therapy alone (OMT). Atotal of five trials were included, comprising 1790 CTO patients, of whom
Like
Comment
Share
